医学
全身疗法
肾细胞癌
肾切除术
内科学
靶向治疗
肿瘤科
肾癌
干扰素
泌尿科
肾
癌症
免疫学
乳腺癌
标识
DOI:10.21037/atm.2019.06.18
摘要
The role of cytoreductive nephrectomy (CN) is changing with improvement of systemic therapy for metastatic renal cell carcinoma (mRCC) patients. In the era of cytokine therapy, immediate CN prior to systemic therapy had been the standard of care for mRCC patients. Two randomized, phase 3 trials demonstrated survival advantages of CN plus interferon therapy over interferon alone with respective median overall survival (OS) of 11.1 versus 8.1 months (1) and 17 versus 7 months (2). However, the first-line treatments for mRCC patients have been replaced by molecular targeted agents in the first decade of the 21st century and are being taken over by immuno-oncology drugs and their combination with targeted agents in the second decade.
科研通智能强力驱动
Strongly Powered by AbleSci AI